Itepekimab for chronic obstructive pulmonary disease therapy

Key Points

• The study aims to evaluate itepekimab as a feasible therapy for managing chronic obstructive pulmonary disease (COPD).
• Review existing clinical data on itepekimab.
• Assess dosing schedules for different disease phases.
• Focus on home administration of therapy.
• Itepekimab may provide effective management for COPD.
• Dosing can be adjusted to every 2 weeks during exacerbations and every 4 weeks when stable.

Abstract